Pelthos Therapeutics announced CEO Scott Plesha's participation in one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026, with press release and company presentation furnished.
Key takeaways
CEO Scott Plesha to participate in one-on-one investor meetings at Piper Sandler Spring Biopharma Symposium on April 16, 2026, in Boston.
Press release (Exhibit 99.1) and company presentation (Exhibit 99.2) made available on April 14, 2026.
ZELSUVMI launched July 2025 as first at-home prescription treatment for Molluscum contagiosum.
Portfolio includes Xepi (impetigo, relaunch late 2026) and Xeglyze (head lice, launch H1 2027).
Key data as of March 16, 2026: stock price $24.00, market cap ~$215M, cash $18.0M at end of 2025.
Phase 3 trials showed Zelsuvmi 58.1% mean lesion reduction vs 35.7% vehicle at week 12.